Suchergebnisse - (Person:"Mullard, Asher")

PubPharm (830)

101

What's next for the synthetic lethality drug discovery engine?

enthalten in: Nature reviews. Drug discovery | 2022

von Mullard, A.

102

BMS buys Turning Point Therapeutics and its kinase inhibitors for $4.1 billion

enthalten in: Nature reviews. Drug discovery | 2022

von Mullard, A.

103

GSK buys Affinivax for up to $3.3 billion, bolstering its vaccine pipeline

enthalten in: Nature reviews. Drug discovery | 2022

von Mullard, A.

104

COVID antibody drugs have saved lives - so why aren't they more popular?

enthalten in: Nature | 2022

von Mullard, A.

105

DNA damage response drugs for cancer yield continued synthetic lethality learnings

enthalten in: Nature reviews. Drug discovery | 2022

von Mullard, A.

106

Do fourth-generation EGFR inhibitors showcase the future of kinase inhibitors?

enthalten in: Nature reviews. Drug discovery | 2022

von Mullard, A.

107

Pull incentives for antibiotics get push from the UK

enthalten in: Nature reviews. Drug discovery | 2022

von Mullard, A.

108

GlaxoSmithKline buys late-stage JAK inhibitor for $1.9 billion

enthalten in: Nature reviews. Drug discovery | 2022

von Mullard, A.

109

Pfizer's small-molecule antiviral misses on COVID prevention

enthalten in: Nature reviews. Drug discovery | 2022

von Mullard, A.

110

FDA approves first cardiac myosin inhibitor

enthalten in: Nature reviews. Drug discovery | 2022

von Mullard, A.